Journal of Proteome Research

Quantum-Si Presents its Vision to Transform Genomics and Proteomics Research at ASHG 2023

Retrieved on: 
Tuesday, October 31, 2023
Research, Technology, Semiconductor, Genetics, Clinical Trials, Health Technology, Biotechnology, Pharmaceutical, Health, Science, ASHG, Genomics, Proteomics, Journal of Proteome Research, Booth, Dicarboxylic acid, Phenotype, Protein, Society, Mass spectrometry, American Society of Human Genetics, Drug discovery, Protein sequencing, Human genetics, Platinum, Munich Information Center for Protein Sequences, Microscope

"Platinum, stands as a groundbreaking advancement in next-generation protein sequencing™ moving the field beyond the limitations posed by mass spectrometry and immunoassays.

Key Points: 
  • "Platinum, stands as a groundbreaking advancement in next-generation protein sequencing™ moving the field beyond the limitations posed by mass spectrometry and immunoassays.
  • This robust tool is a solution, enabling precise, single-molecule resolution," remarked Quantum-Si Chief Executive Officer Jeff Hawkins.
  • Additionally, on Thursday, November 2, at 4:30 p.m., Quantum-Si scientists will present: Unleashing Next-generation Protein Sequencing™ with Platinum™: How it will Transform Genomics and Proteomics Research .
  • Its elegant design and simple workflow enable broad-scale access to proteomic data, for every scientist, everywhere, making it a groundbreaking platform for the future of proteomics research.

CAS Convenes Life Sciences Advisory Board to Reimagine the Future of Scientific Discovery

Retrieved on: 
Wednesday, April 5, 2023
Science, Thought Leadership, Other Science, Biotechnology, Research, Pharmaceutical, Health, Professional Services, Molecule, Digital Transformation Agency, Novartis Institute for Tropical Diseases, Biomedical Research, University, Senior, Life, Small molecule, Workflow, Takeda, CSO, Roche, New product development, The central science, Warren Center, Pennsylvania, Vanderbilt University, Antibody, Organization, Institute of Physics, Journal, American Chemical Society, HIV disease progression rates, Scripps Research, Journal of Proteome Research, Investment, Patient, Digital transformation, Drug discovery, CAS, Physics, Decision support system, Management, Pharmaceutical industry, Medical device

CAS, a division of the American Chemical Society specializing in scientific information solutions, announced today its CAS Life Sciences Advisory Board.

Key Points: 
  • CAS, a division of the American Chemical Society specializing in scientific information solutions, announced today its CAS Life Sciences Advisory Board.
  • The board comprises a world-class panel of global thought leaders, directing the CAS scientific journey to align authoritative content with groundbreaking predictive technologies that span the spectrum of life sciences workflows.
  • CAS also continues to recruit additional members to ensure broad diversity and engagement.
  • “We are privileged to have this team of passionate global industry leaders partner with CAS to help drive new innovations in drug discovery,” said Manuel Guzman, President, CAS.

Bertis Establishes U.S. Operations to Bring Novel Proteomics-Based Diagnostics to the U.S. Market

Retrieved on: 
Tuesday, October 11, 2022
Proteomics, LinkedIn, Pancreatic cancer, CLIA, Medicine, Korean Intellectual Property Office, Diagnosis, Machine learning, Korean Ministry of Culture, Patient, Hospital, American Chemical Society, Raffles Medical Group, Research, Disorder, Cancer, Multimedia, Artificial intelligence, Precision medicine, Technology, Cancer Breakthroughs 2020, PASS, Solution, Human body, Biomarker, Raffles, National Cancer Institute, AI, Breast cancer, PMID, American, Ministry of Food and Drug Safety, Protein, Journal, Proteome, Plasma, Ministry, NET, Ovarian cancer, Journal of Proteome Research, View, Pharmaceutical industry, Medical device, Medical imaging, Dentistry, Bertie the Brain, Food

SEOUL, Korea, Oct. 11, 2022 /PRNewswire/ -- Bertis Inc., a South Korean proteomics-based precision medicine technology company, announced today it has established a U.S.-based wholly-owned entity to expand the company's global presence and primarily provide access to the growing U.S. clinical testing market.

Key Points: 
  • The company has successfully commercialized in South Korea MASTOCHECKTM, the world's first proteomics-based breast cancer blood test solution.
  • Bertis has gained a foothold in the Asian market by recently signing a contract with one of Singapore's largest medical groups, Raffles Medical Group, to supply MASTOCHECKTM.
  • Recently, Bertis' research team presented protein biomarkers for early diagnosis of high-grade serous ovarian cancer (HGSOC) with 95% accuracy4.
  • Bertis' capabilities range from cancer, disorder biomarker discovery, low-cost diagnostics manufacturing and analysis services.

Bertis Announces Proteomic Based Research Results of New Biomarker for Ovarian Cancer Diagnosis

Retrieved on: 
Tuesday, September 6, 2022
Oncology, Health, Consumer, Women, Clinical Trials, Pharmaceutical, Biotechnology, Breast cancer, Technology, American Chemical Society, Cancer, American, Survival, Research, Survival rate, PLOS, Pancreatic cancer, Journal of Proteome Research, Diagnosis, Protein, Solution, Death, Precision medicine, Gynecologic cancer disparities in the United States, Medicine, Multiomics, Blood, Ovarian cancer, LinkedIn, Proteome, Prognosis, JAMA Surgery, Hyperthermic intraperitoneal chemotherapy, Obstetrics, Multimedia, Method, Journal, PASS, Plasma, Biomarker, Gynaecology, Chief executive officer, Discovery, Health, Proteomics, Patient, Birth control, Medical imaging, Bertie Reed

View the full release here: https://www.businesswire.com/news/home/20220905005058/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220905005058/en/
    Discovery process of high-grade serous ovarian cancer (HGSOC) biomarker candidates (Graphic: Business Wire)
    Ovarian cancer is the first leading cause of death among gynecological cancers.
  • The results of this research were published in the September issue of the Journal of Proteome Research on the 2nd by the American Chemical Society.
  • In this study, the research team identified 18 candidate proteins after quantifying 1,847 serum proteins, the highest number ever reported as ovarian cancer biomarker research results, through Bertis technology platform to discover biomarker candidates.
  • Currently, Bertis is researching and developing early diagnosis solutions for pancreatic cancer, ovarian cancer, etc.